|
 |
gemifloxacin mesylateThis page contains recent news articles, when available, and an overview of gemifloxacin mesylate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Factive (gemifloxacin mesylate) is available for the treatment of acute bacterial exacerbations of chronic bronchitis and mild to moderate ... Pay-Per-View - Family Practice News - Factiva, from Dow Jones Oscient Pharmaceuticals Announces Results of FDA Advisory Committee … - Sep 13, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... RedOrbit Bloomberg Printer-Friendly Page - Nov 2, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Bloomberg A Year in Review and Looking Ahead: New Pharmaceutical Treatment … - Dec 8, 2005 Gemifloxacin mesylate, which is given daily (320 mg for 5 to 7 days), is a new fluoroquinolone antibacterial agent indicated for treatment of ... Medscape Regulatory Filing for FACTIVE Tablets Submitted in Europe - May 7, 2008 Oscient Pharmaceuticals Corporation's (Nasdaq: OSCI) commercialization partner for FACTIVE(R) (gemifloxacin mesylate) tablets, Menarini Group, ... Genetic Engineering News - Genetic Engineering News (press release) Webcast Alert: Oscient Pharmaceuticals to Present at the 9th Annual … - Nov 8, 2007 FACTIVE ® (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... businesswire.com Abbott Canada Launches Oscient Pharmaceuticals' FACTIVE Tablets in … - Aug 22, 2006 FACTIVE ® (gemifloxacin mesylate) tablets is an antibiotic approved in the US for the five-day treatment of acute bacterial exacerbations of chronic ... businesswire.com Oscient Pharmaceuticals to Present at 25th Annual JPMorgan Healthcare... - Jan 11, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals to Present at Roth Capital Partners 18th... - Feb 21, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... businesswire.com Webcast Alert: Oscient Pharmaceuticals to Present at BIO CEO &... - Feb 9, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... RedOrbit Oscient Pharmaceuticals Provides Preliminary Revenue Results for... - Apr 16, 2008 The Company reiterates its previously announced guidance of $96-$103 million in revenues from ANTARA and FACTIVE(R) (gemifloxacin mesylate) tablets in 2008 ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals to Present at Roth Capital Partners New York ... - Aug 31, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... RedOrbit Oscient Pharmaceuticals Reports Third Quarter 2008 Financial Results - Nov 4, 2008 Revenues from the antibiotic FACTIVE ® (gemifloxacin mesylate) tablets totaled $3.7 million in the third quarter of 2008, compared to $2.8 million in the ... International Business Times Oscient Pharmaceuticals Provides Preliminary Revenue Results for the ... - Jul 13, 2007 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals to Present at CE Unterberg, Towbin Emerging … - Oct 26, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... businesswire.com Regulatory Filing For FACTIVE Tablets Submitted In Europe - May 9, 2008 Oscient Pharmaceuticals Corporation's (Nasdaq: OSCI) commercialization partner for FACTIVE® (gemifloxacin mesylate) tablets, Menarini Group, ... Medical News Today - Medical News Today (press release) Oscient Pharmaceuticals Completes Acquisition of Cardiovascular … - Aug 21, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... RedOrbit FDA Approves Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five- … - May 2, 2007 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals to Present at Thomas Weisel Healthcare … - Sep 9, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... businesswire.com Oscient Pharmaceuticals Reports Second Quarter 2008 Financial Results - Aug 1, 2008 ...$18.4 million in revenue from the cardiovascular drug ANTARA and $1.9 million in revenue from the antibiotic FACTIVE(R) (gemifloxacin mesylate) tablets. ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals and Pfizer, SA de CV Announce Approval of … - Aug 1, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals Provides Preliminary Revenue Results for the ... - Oct 10, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals Completes Enrollment in Pivotal Phase III … - Mar 9, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... RedOrbit Oscient Pharmaceuticals to Participate in the Rodman & Renshaw 10th … - Nov 5, 2008 ...of the Company;Â highlight details on the recent market performance of ANTARA ® (fenofibrate) capsules and FACTIVE ® (gemifloxacin mesylate) tablets; ... International Business Times Oscient Pharmaceuticals Receives Approvable Letter from FDA for … - Sep 22, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals Provides Preliminary Revenue Results for the ... - Apr 11, 2007 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - Business Wire - AccessMyLibrary.com Full Results Released From Phase III Trial Comparing Five-Day and … - Sep 18, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... RedOrbit FinancialContent.com - Stock Quotes and Business News - Aug 12, 2008 ...highlight details on the recent market performance of ANTARA®(fenofibrate) capsules and FACTIVE® (gemifloxacin mesylate) tablets; and discuss the ... cbs5.com OSCIENT EXPECTS TOTAL REVENUES OF $23 MILLION FOR Q1 2007. … - May 1, 2007 FACTIVE (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... $4.95 - Biotech Financial Reports - ECNext Oscient Pharmaceuticals Amends FACTIVE License Agreement with LG … - Dec 29, 2006 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - Business Wire - AccessMyLibrary.com Clinical Data on FACTIVE(R) Tablets to be Presented at the 43rd... - Oct 7, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... businesswire.com Oscient Pharmaceuticals Agrees to Acquire Cardiovascular Therapy … - Jul 24, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals Reports Financial Results for Second Quarter ... - Aug 2, 2007 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals to Present at Fourth Annual JMP Securities … - Mar 2, 2005 The Company is marketing FACTIVE (R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... businesswire.com Abbott Canada Launches Oscient Pharmaceuticals' FACTIVE Tablets in … - Mar 2, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved in the US for the five-day treatment of acute bacterial exacerbations of chronic ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals to Present at Rodman & Renshaw 8th Annual … - Oct 30, 2006 The Company markets two products: FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of ... Genetic Engineering News - Genetic Engineering News (press release) Press Release: Menarini Group - SWOT Analysis. - M2 Presswire | … - Sep 30, 2008 Movers: Oscient Pharmaceuticals and Menarini Group Enter into European Agreement(C ... gemifloxacin mesylate) tablets in Europe to Menarini Group, ... Pay-Per-View - M2 Presswire - HighBeam Research Oscient Pharmaceuticals to Present at Fourth Annual JMP Securities … - Feb 23, 2005 The Company is marketing FACTIVE (R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals to Present at Rodman & Renshaw 8th Annual … - Nov 6, 2006 The Company markets two products: FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of ... businesswire.com Oscient Pharmaceuticals Reports Financial Results for Third Quarter … - Oct 31, 2007 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - Business Wire - AccessMyLibrary.com Press Release: Menarini Group - SWOT Analysis. - M2 Presswire | … - Aug 28, 2008 Movers: Oscient Pharmaceuticals and Menarini Group Enter into European Agreement(C ... gemifloxacin mesylate) tablets in Europe to Menarini Group, ... Pay-Per-View - M2 Presswire - HighBeam Research Oscient Pharmaceuticals to Present at JP Morgan Annual Healthcare … - Jan 10, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... RedOrbit Oscient Pharmaceuticals Announces Meeting Date for FDA Advisory … - Jun 28, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals and Menarini Group Enter into European … - Jan 4, 2007 FACTIVE (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - M2 Presswire - AccessMyLibrary.com Clinical Data on FACTIVE(R) Tablets to Be Presented at the 43rd... - Sep 30, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... RedOrbit Article: INVESTING AIG Asked to Delay ... - The Washington Post | … - May 13, 2008 Health & Medicine Week; May 19, 2008 ; 660 words ... ... gemifloxacin mesylate) tablets, Menarini Group, a leading European pharmaceutical company based in ... Pay-Per-View - Washington Post - HighBeam Research FDA Accepts As ``Complete Response'' Oscient Pharmaceuticals' … - Nov 27, 2006 FACTIVE® (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... RedOrbit July Issue of Journal of Antimicrobial Chemotherapy Highlights Study... - Jun 12, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis and. Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals Achieves Primary Endpoint in Phase III Trial... - Jun 6, 2005 The Company is marketing FACTIVE (R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... RedOrbit Oscient Pharmaceuticals and Abbott Canada Enter into … - Aug 10, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... RedOrbit Press Release: Oscient Pharmaceuticals Provides Financial Projections... - Jan 1, 2007 FACTIVE® (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... FierceBiotech New Data on FACTIVE(R) Tablets and Ramoplanin Presented at the 45th … - Dec 16, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... businesswire.com Oscient Pharmaceuticals Provides Preliminary Revenue Results for... - Oct 11, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals Completes Enrollment in Phase IV Trial of … - Jan 26, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals to Present at First Albany Capital Annual... - Dec 6, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... businesswire.com Oscient Pharmaceuticals' FACTIVE Tablets Subject of Poster … - Apr 4, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... RedOrbit Oscient Pharmaceuticals to Present at 24th Annual JPMorgan Healthcare... - Jan 9, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... businesswire.com Oscient Pharmaceuticals Reports Financial Results for Fourth Quarter ... - Mar 6, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic b. Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals to Present at Fifth Annual JMP Securities … - Mar 2, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... Free with registration - Business Wire - AccessMyLibrary.com CORRECTED: Webcast Alert: Oscient Pharmaceuticals to Present at … - Mar 8, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals to Present at the JMP Securities Sector Focus... - Nov 13, 2006 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals Provides Financial Projections for Fiscal... - Dec 8, 2006 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Genetic Engineering News - Genetic Engineering News (press release) FACTIVE(R) Tablets Subject of Five Presentations at Third Internationa... - Oct 9, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals to Participate in the Sixth Annual JMP... - May 15, 2007 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Genetic Engineering News - Genetic Engineering News (press release) Oscient Pharmaceuticals to Present at Fifth Annual JMP Securities … - Mar 9, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... businesswire.com Oscient Pharmaceuticals to Present at the JMP Securities Sector Focus... - Nov 16, 2006 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... businesswire.com Oscient Pharmaceuticals to Present at 25th Annual JPMorgan Healthcare... - Dec 19, 2006 FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... Free with registration - Business Wire - AccessMyLibrary.com Data on FACTIVE(R) Tablets Short-Course Therapy in Patients with Co- … - Oct 13, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... Free with registration - Business Wire - AccessMyLibrary.com Oscient Pharmaceuticals and Pfizer Enter Agreement for FACTIVE … - Feb 7, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... RedOrbit CORRECTED: Webcast Alert: Oscient Pharmaceuticals to Present at … - Mar 15, 2007 FACTIVE ® (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... businesswire.com Oscient Pharmaceuticals Reports Financial Results for First Quarter... - Mar 31, 2007 FACTIVE ® (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... businesswire.com Oscient Pharmaceuticals to Present at Thomas Weisel Healthcare … - Sep 6, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... businesswire.com Oscient Pharmaceuticals to Participate in the Acumen BioFin Rodman & ... - Oct 29, 2007 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... $4.95 - Business Wire - ECNext Oscient Pharmaceuticals to Present at Thomas Weisel Healthcare … - Aug 30, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - Business Wire - ECNext Oscient Pharmaceuticals to Participate in the Natixis Bleichroeder... - Oct 1, 2007 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... $4.95 - Business Wire - ECNext Oscient Pharmaceuticals to Present at CE Unterberg, Towbin Emerging … - Oct 19, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of ... $4.95 - Business Wire - ECNext Oscient Pharmaceuticals to Participate in the 19th Annual Piper... - Nov 20, 2007 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... $4.95 - Business Wire - ECNext Auxilium Pharmaceuticals and Oscient Pharmaceuticals Establish Co- … - Apr 13, 2005 Oscient is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - Business Wire - ECNext Oscient Pharmaceuticals to Present at Thomas Weisel Healthcare … - Sep 2, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - Business Wire - ECNext Webcast Alert: Oscient Pharmaceuticals to Present at Pacific Growth … - Jun 1, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - Business Wire - ECNext Oscient Pharmaceuticals and LG Life Sciences Amend FACTIVE License … - Apr 6, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - Business Wire - ECNext Personnel; Pharmaceutical company expands sales force, names new … - Apr 18, 2005 The sales force is currently concentrating on the commercialization of FACTIVE (gemifloxacin mesylate) tablets. Oscient began selling FACTIVE in September ... Pay-Per-View - Pharma Business Week - Factiva, from Dow Jones Oscient Pharmaceuticals Reports Financial Results for First Quarter; ... - May 2, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - Business Wire - ECNext Oscient Pharmaceuticals Completes Sales Force Expansion; Company … - Oct 3, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - Business Wire - ECNext Oscient Pharmaceuticals Completes Nationwide FACTIVE Sales Force … - Mar 18, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - Business Wire - ECNext Oscient Pharmaceuticals Reports Financial Results for Second Quarter... - Aug 2, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - Business Wire - ECNext OSCIENT COMPLETES ENROLLMENT IN PHASE IV OF FACTIVE … - Mar 1, 2007 FACTIVE (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... $4.95 - Biotech Business - ECNext Auxilium Pharmaceuticals' CEO to Participate in Oscient Pharmaceutical... - Apr 28, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - PR Newswire - ECNext Oscient Pharmaceuticals to Present at JP Morgan Annual Healthcare … - Jan 3, 2005 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - Business Wire - ECNext Oscient Pharmaceuticals Stock Trading Halted Today; FDA Advisory … - Sep 12, 2006 The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - Business Wire - ECNext FDA submissions, approvals and other actions: September 2006.(Report) - Oct 16, 2006 Oscient Factive Gemifloxacin mesylate; Pharmaceuticals (FDA-approved) a fluoroquinolone Corp. (OSCI) antibiotic Oscient Factive Gemifloxacin mesylate; ... Pay-Per-View - Bioworld Financial Watch - Factiva, from Dow Jones Personnel; Pharmaceutical company expands sales force, names new … - Apr 19, 2005 The sales force is currently concentrating on the commercialization of FACTIVE (gemifloxacin mesylate) tablets. Oscient began selling FACTIVE in September ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Personnel; Pharmaceutical company expands sales force, names new … - Apr 23, 2005 The sales force is currently concentrating on the commercialization of FACTIVE (gemifloxacin mesylate) tablets. Oscient began selling FACTIVE in September ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Oscient Pharmaceuticals Names Gary Patou, MD, to Board of Directors. - Mar 22, 2005 The Company is marketing FACTIVE (R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... $4.95 - Business Wire - ECNext Oscient Pharmaceuticals to Participate in the BMO Capital Markets... - Nov 28, 2007 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... $4.95 - Business Wire - ECNext New Treatment Guidelines for Community-Acquired Pneumonia Highlight … - Feb 22, 2007 FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and ... $4.95 - Business Wire - ECNext Bloomberg Printer-Friendly Page - Dec 3, 2007 ANTARA(R) (fenofibrate) capsules, a cardiovascular product and FACTIVE(R) (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ... Bloomberg Bloomberg Printer-Friendly Page - Dec 10, 2007 ANTARA(R) (fenofibrate) capsules, a cardiovascular product and FACTIVE(R) (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ... Bloomberg Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of ... - Feb 1, 2008 ANTARA(R) (fenofibrate) capsules, a cardiovascular product and FACTIVE(R) (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ... Free with registration - PR Newswire - AccessMyLibrary.com Oscient Pharmaceuticals Announces Determination of the Consideration ... - Nov 20, 2008 United States: ANTARA ® (fenofibrate) capsules, a cardiovascular product and FACTIVE ® (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ... International Business Times |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |